Could your own tumor cells fight cancer? early trial tests new approach
NCT ID NCT05417750
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 36 times
Summary
This early-phase study tested a personalized therapy where immune cells are taken from a patient's own tumor, grown in large numbers in a lab, and then infused back into the patient. The goal was to see if this treatment is safe and can shrink advanced solid tumors like melanoma, cervical cancer, and lung cancer. The trial enrolled 43 adults and also gave them a drug called sintilimab to boost the immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100039, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tumor-infiltrating lymphocytes (TIL) plus sintilimab
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors like melanoma and cervical cancer.
What could go wrong
This is a very early Phase 1 trial with only 43 participants, so safety and effectiveness are not yet proven. The treatment involves intensive chemotherapy beforehand and may cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.